Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Were Hedge Funds Right Betting on These Five Stocks in Q1?

Investing in large-cap stocks offer investors a lower exposure to risk from, but they are still prone to volatility, often mimicking the trajectory of the broader market. Moreover, since many smart money investors often have a significant exposure to some large and mega-cap stocks, their drop on the back of unpredictable developments can cause significant pain, which has been recently proven by Valeant Pharmaceuticals. At Insider Monkey, we follow close to 800 hedge funds and other institutional investors, whose 13F portfolios we analyze every quarter and see in which stocks they prefer to invest their capital. Given that the first quarter has just ended, let’s take a look at the performance of the top five stocks, that ranked as the most popular among the funds we track and see if the investors made the right choice betting on them.

The main reason why we track the activity of these funds is our small-cap strategy, which showed that one of the more efficient ways to generate alpha by imitating hedge funds is by following them into the small-cap stocks they are collectively bullish on (see more details here).

Let’s start with Allergan plc Ordinary Shares (NYSE:AGN), which during the last quarter of 2015 saw the number of funds long the stock go up to 159 from 151, which helped it maintain the top spot as the most popular stock among the funds in our database, and the funds from our database amassed more than 18% of the company’s stock heading into 2016. The growth in popularity came amid the announcement of Pfizer’s plans to acquire Allergan in a $160 billion deal. Allergan plc Ordinary Shares (NYSE:AGN)’s stock lost 14% during the fourth quarter, as investors started to become more skeptical regarding the deal, which would represent the largest inversion (Pfizer plans to relocate its headquarters to Dublin after the acquisition to lower its corporate taxes) and might encounter problems while seeking approval from regulators. Nevertheless, both companies have assured that the deal should be completed in the second half of 2016. Among the top shareholders of Allergan plc Ordinary Shares (NYSE:AGN) are Andreas Halvorsen’s Viking Global, Dan Loeb’s Third Point and Paul Singer’s Elliott Management.

Follow Allergan Plc (NYSE:AGN)
Trade (NYSE:AGN) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.